世界のトランスサイレチンアミロイド心筋症（ATTR-CM）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z5731
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、91ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、トランスサイレチンアミロイド心筋症（ATTR-CM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（トランスサイレチン安定剤、非ステロイド性抗炎症薬（NSAID）、RNAi療法、その他）、用途別市場規模（遺伝性トランスサイレチンアミロイドーシス（hATTR）、野生型トランスサイレチンアミロイドーシス（wtATTR））、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療の市場動向
・企業の競争状況、市場シェア
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療の種類別市場規模（トランスサイレチン安定剤、非ステロイド性抗炎症薬（NSAID）、RNAi療法、その他）
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療の用途別市場規模（遺伝性トランスサイレチンアミロイドーシス（hATTR）、野生型トランスサイレチンアミロイドーシス（wtATTR））
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療の北米市場規模2016-2027（アメリカ、カナダ）
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・トランスサイレチンアミロイド心筋症（ATTR-CM）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Pfizer Inc、GlaxoSmithKline Plc、Eidos Therapeutics、Ionis Pharmaceuticals, Inc、Alnylam Pharmaceuticals、Prothena Corporation Plc、Intellia Therapeutics, Inc、Corino Therapeutics, Inc）
・結論

Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.

Market Analysis and Insights: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market.

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Scope and Market Size
Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
RNAi Therapy
Others

Segment by Application
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer Inc
GlaxoSmithKline Plc
Eidos Therapeutics
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals
Prothena Corporation Plc
Intellia Therapeutics, Inc
Corino Therapeutics, Inc

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Transthyretin Stabilizers
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
1.2.4 RNAi Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2016-2027)
2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Regions
2.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Dynamic
2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2016-2021)
3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type
4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027)

5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application
5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
6.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
6.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
6.2.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
6.3.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
6.3.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
6.3.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
6.4.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
6.4.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
7.2.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
7.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
7.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
8.2.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
8.3.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region
8.4.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
9.2.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
9.3.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
9.4.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type
10.2.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
10.3.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country
10.4.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Details
11.1.2 Pfizer Inc Business Overview
11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.1.5 Pfizer Inc Recent Development
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Details
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.2.5 GlaxoSmithKline Plc Recent Development
11.3 Eidos Therapeutics
11.3.1 Eidos Therapeutics Company Details
11.3.2 Eidos Therapeutics Business Overview
11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.3.5 Eidos Therapeutics Recent Development
11.4 Ionis Pharmaceuticals, Inc
11.4.1 Ionis Pharmaceuticals, Inc Company Details
11.4.2 Ionis Pharmaceuticals, Inc Business Overview
11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.4.5 Ionis Pharmaceuticals, Inc Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Prothena Corporation Plc
11.6.1 Prothena Corporation Plc Company Details
11.6.2 Prothena Corporation Plc Business Overview
11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.6.5 Prothena Corporation Plc Recent Development
11.7 Intellia Therapeutics, Inc
11.7.1 Intellia Therapeutics, Inc Company Details
11.7.2 Intellia Therapeutics, Inc Business Overview
11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.7.5 Intellia Therapeutics, Inc Recent Development
11.8 Corino Therapeutics, Inc
11.8.1 Corino Therapeutics, Inc Company Details
11.8.2 Corino Therapeutics, Inc Business Overview
11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
11.8.5 Corino Therapeutics, Inc Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Transthyretin Stabilizers
Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID)
Table 4. Key Players of RNAi Therapy
Table 5. Key Players of Others
Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2016-2021)
Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
Table 12. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
Table 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
Table 14. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
Table 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players (2016-2021)
Table 18. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020)
Table 19. Ranking of Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
Table 23. Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Pfizer Inc Company Details
Table 64. Pfizer Inc Business Overview
Table 65. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 66. Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 67. Pfizer Inc Recent Development
Table 68. GlaxoSmithKline Plc Company Details
Table 69. GlaxoSmithKline Plc Business Overview
Table 70. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 71. GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 72. GlaxoSmithKline Plc Recent Development
Table 73. Eidos Therapeutics Company Details
Table 74. Eidos Therapeutics Business Overview
Table 75. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 76. Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 77. Eidos Therapeutics Recent Development
Table 78. Ionis Pharmaceuticals, Inc Company Details
Table 79. Ionis Pharmaceuticals, Inc Business Overview
Table 80. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 81. Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 82. Ionis Pharmaceuticals, Inc Recent Development
Table 83. Alnylam Pharmaceuticals Company Details
Table 84. Alnylam Pharmaceuticals Business Overview
Table 85. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 86. Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 87. Alnylam Pharmaceuticals Recent Development
Table 88. Prothena Corporation Plc Company Details
Table 89. Prothena Corporation Plc Business Overview
Table 90. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 91. Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 92. Prothena Corporation Plc Recent Development
Table 93. Intellia Therapeutics, Inc Company Details
Table 94. Intellia Therapeutics, Inc Business Overview
Table 95. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 96. Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 97. Intellia Therapeutics, Inc Recent Development
Table 98. Corino Therapeutics, Inc Company Details
Table 99. Corino Therapeutics, Inc Business Overview
Table 100. Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021) & (US$ Million)
Table 101. Corino Therapeutics, Inc Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Transthyretin Stabilizers Features
Figure 3. Nonsteroidal Anti-inflammatory Drugs (NSAID) Features
Figure 4. RNAi Therapy Features
Figure 5. Others Features
Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hereditary Transthyretin Amyloidosis (hATTR) Case Studies
Figure 8. Wild Type Transthyretin Amyloidosis (wtATTR) Case Studies
Figure 9. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered
Figure 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Regions (2022-2027)
Figure 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players in 2020
Figure 15. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2020
Figure 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 21. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 22. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 23. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 27. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 28. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 29. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2016-2027)
Figure 39. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Pfizer Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 59. GlaxoSmithKline Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 60. Eidos Therapeutics Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 61. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 62. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 63. Prothena Corporation Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 64. Intellia Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 65. Corino Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Global Transthyretin Amyloidosis (ATTR) Market Size, Status and Forecast 2021-2027
QYR2104Z5732 2021年4月 93Pages
QYResearch社発行の本調査資料では、トランスサイレチンアミロイドーシス（ATTR）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（遺伝性ATTR（HATTR）、野生型（WT）ATTR）、用途別市場規模（病院、外来手術センター、診断センタ...

世界の肥大型心筋症（HCM）治療市場規模・現状・予測（2021年-2027年）

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z3003 2021年4月 98Pages
QYResearch社発行の本調査資料では、肥大型心筋症（HCM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（βアドレナリン遮断薬、カルシウムチャネル遮断薬、抗不整脈薬、抗凝固薬、その他）、用途別市場規模（病院薬局、小売薬局）、主要地域...

世界の肥大型心筋症治療市場規模・現状・予測（2021年-2027年）

Global Hypertrophic Cardiomyopathy Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z3004 2021年4月 94Pages
QYResearch社発行の本調査資料では、肥大型心筋症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（カルシウムチャネル遮断薬、抗不整脈薬、βアドレナリン遮断薬、抗凝固薬、その他）、用途別市場規模（病院、診療所、外来手術センター、学術・研...

世界の家族性アミロイド多発神経障害市場規模・現状・予測（2021年-2027年）

Global Familial Amyloid Polyneuropathy Market Size, Status and Forecast 2021-2027
QYR2104Z2314 2021年4月 96Pages
QYResearch社発行の本調査資料では、家族性アミロイド多発神経障害のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（FAP-I、FAP-II、FAP-III、FAP-IV）、用途別市場規模（病院・クリニック、その他）、主要地域別市場規模（北...

世界の家族性アミロイド多発神経障害市場規模・現状・予測（2021年-2027年）

世界の拡張型心筋症治療市場規模・現状・予測（2021年-2027年）

Global Dilated Cardiomyopathy Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1896 2021年4月 93Pages
QYResearch社発行の本調査資料では、拡張型心筋症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬剤、植込み型除細動器）、用途別市場規模（子供、成人、高齢者）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国...

世界の自閉症スペクトラム障害（ASD）治療市場規模・現状・予測（2021年-2027年）

Global Autism Spectrum Disorder (ASD) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0511 2021年4月 98Pages
QYResearch社発行の本調査資料では、自閉症スペクトラム障害（ASD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（応用行動分析（ABA）、離散試験トレーニング（DTT）、ピボット応答トレーニング（PRT）、その他）、用途別市場規模...

世界の筋萎縮性側索硬化症（ALS）治療市場規模・現状・予測（2021年-2027年）

Global Amyotrophic Lateral Sclerosis Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0303 2021年4月 90Pages
QYResearch社発行の本調査資料では、筋萎縮性側索硬化症（ALS）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物療法、理学療法、言語療法、その他）、用途別市場規模（病院、専門センター、研究センター、その他）、主要地域別市場規模（...

世界の男性不妊症診断・治療市場規模・現状・予測（2021年-2027年）

Global Male Infertility Diagnosis and Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3537 2021年4月 90Pages
QYResearch社発行の本調査資料では、男性不妊症診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（治療薬・医薬品、手術用マーカー、生殖補助医療（ART））、用途別市場規模（病院・クリニック、診断センター）、主要地域別市場規模（北米...

世界の食物アレルギー診断・治療市場規模・現状・予測（2021年-2027年）

Global Food Allergy Diagnosis and Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z2428 2021年4月 99Pages
QYResearch社発行の本調査資料では、食物アレルギー診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（プリック検査、血液検査、食物除去検査、ポリメラーゼ連鎖反応（PCR）、酵素免疫測定法（ELISA）、その他）、用途別市場規模（抗...

世界のトランスサイレチンアミロイドーシス（ATTR）市場規模・現状・予測（2021年-2027年） Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point m…
世界の拡張型心筋症治療市場規模・現状・予測（2021年-2027年） Dilated Cardiomyopathy (DCM) is a condition in which heart's left ventricle, is enlarged and weakened and the ability to pump blood is decreased. The growth in DCM treatment market is due to prominent rise in number of heart failure patients worldwide over the years, R&D activities and increased awa…
世界の非ステロイド性抗炎症薬（NSAID）市場規模・現状・予測（2021年-2027年） Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class that reduce pain, decrease fever, prevent blood clots and, in higher doses, decrease inflammation. Side effects depend on the specific drug, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack and ki…
世界の家族性アミロイド多発神経障害市場規模・現状・予測（2021年-2027年） Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Globally, development of new dru…
世界の家族性アミロイド多発神経障害市場規模・現状・予測（2021年-2027年） Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Globally, development of new dru…